The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gene Knockdown-Global Market Insights and Sales Trends 2024
Synopsis
The global Gene Knockdown market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Knockdown in various end use industries. The expanding demands from the Medical, Bioengineering and Other, are propelling Gene Knockdown market. siRNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the shRNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Gene Knockdown market, driven by demand from China, the second largest economy with some signs of stabilising, the Gene Knockdown market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Knockdown, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Knockdown market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Knockdown market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Knockdown sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Knockdown covered in this report include Santa Cruz Biotechnology (US), OriGene (US), Sigma-Aldrich (US), Abnova (Taiwan), Agilent Technologies (US), Bio-Rad (US), Cell Signaling Technology (US), GeneCopoeia (US) and siTOOLs Biotech (Germany), etc.
The global Gene Knockdown market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Santa Cruz Biotechnology (US)
OriGene (US)
Sigma-Aldrich (US)
Abnova (Taiwan)
Agilent Technologies (US)
Bio-Rad (US)
Cell Signaling Technology (US)
GeneCopoeia (US)
siTOOLs Biotech (Germany)
Novus Biologicals (US)
EMD Millipore (US)
BioVision (US)
Creative Biomart (US)
Selleck Chemicals (US)
MyBioSource (US)
Invitrogen (US)
Qiagen (Germany)
Global Gene Knockdown market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Knockdown market, Segment by Type:
siRNA
shRNA
Other
Global Gene Knockdown market, by Application
Medical
Bioengineering
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Knockdown companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Gene Knockdown market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gene Knockdown in various end use industries. The expanding demands from the Medical, Bioengineering and Other, are propelling Gene Knockdown market. siRNA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the shRNA segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Gene Knockdown market, driven by demand from China, the second largest economy with some signs of stabilising, the Gene Knockdown market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gene Knockdown, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gene Knockdown market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gene Knockdown market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gene Knockdown sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gene Knockdown covered in this report include Santa Cruz Biotechnology (US), OriGene (US), Sigma-Aldrich (US), Abnova (Taiwan), Agilent Technologies (US), Bio-Rad (US), Cell Signaling Technology (US), GeneCopoeia (US) and siTOOLs Biotech (Germany), etc.
The global Gene Knockdown market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Santa Cruz Biotechnology (US)
OriGene (US)
Sigma-Aldrich (US)
Abnova (Taiwan)
Agilent Technologies (US)
Bio-Rad (US)
Cell Signaling Technology (US)
GeneCopoeia (US)
siTOOLs Biotech (Germany)
Novus Biologicals (US)
EMD Millipore (US)
BioVision (US)
Creative Biomart (US)
Selleck Chemicals (US)
MyBioSource (US)
Invitrogen (US)
Qiagen (Germany)
Global Gene Knockdown market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gene Knockdown market, Segment by Type:
siRNA
shRNA
Other
Global Gene Knockdown market, by Application
Medical
Bioengineering
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gene Knockdown companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gene Knockdown
1.1 Gene Knockdown Market Overview
1.1.1 Gene Knockdown Product Scope
1.1.2 Gene Knockdown Market Status and Outlook
1.2 Global Gene Knockdown Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gene Knockdown Market Size by Region (2018-2029)
1.4 Global Gene Knockdown Historic Market Size by Region (2018-2023)
1.5 Global Gene Knockdown Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gene Knockdown Market Size (2018-2029)
1.6.1 North America Gene Knockdown Market Size (2018-2029)
1.6.2 Europe Gene Knockdown Market Size (2018-2029)
1.6.3 Asia-Pacific Gene Knockdown Market Size (2018-2029)
1.6.4 Latin America Gene Knockdown Market Size (2018-2029)
1.6.5 Middle East & Africa Gene Knockdown Market Size (2018-2029)
2 Gene Knockdown Market by Type
2.1 Introduction
2.1.1 siRNA
2.1.2 shRNA
2.1.3 Other
2.2 Global Gene Knockdown Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gene Knockdown Historic Market Size by Type (2018-2023)
2.2.2 Global Gene Knockdown Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gene Knockdown Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gene Knockdown Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gene Knockdown Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gene Knockdown Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gene Knockdown Revenue Breakdown by Type (2018-2029)
3 Gene Knockdown Market Overview by Application
3.1 Introduction
3.1.1 Medical
3.1.2 Bioengineering
3.1.3 Other
3.2 Global Gene Knockdown Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gene Knockdown Historic Market Size by Application (2018-2023)
3.2.2 Global Gene Knockdown Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gene Knockdown Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gene Knockdown Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gene Knockdown Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gene Knockdown Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gene Knockdown Revenue Breakdown by Application (2018-2029)
4 Gene Knockdown Competition Analysis by Players
4.1 Global Gene Knockdown Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Knockdown as of 2022)
4.3 Date of Key Players Enter into Gene Knockdown Market
4.4 Global Top Players Gene Knockdown Headquarters and Area Served
4.5 Key Players Gene Knockdown Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Knockdown Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Santa Cruz Biotechnology (US)
5.1.1 Santa Cruz Biotechnology (US) Profile
5.1.2 Santa Cruz Biotechnology (US) Main Business
5.1.3 Santa Cruz Biotechnology (US) Gene Knockdown Products, Services and Solutions
5.1.4 Santa Cruz Biotechnology (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.1.5 Santa Cruz Biotechnology (US) Recent Developments
5.2 OriGene (US)
5.2.1 OriGene (US) Profile
5.2.2 OriGene (US) Main Business
5.2.3 OriGene (US) Gene Knockdown Products, Services and Solutions
5.2.4 OriGene (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.2.5 OriGene (US) Recent Developments
5.3 Sigma-Aldrich (US)
5.3.1 Sigma-Aldrich (US) Profile
5.3.2 Sigma-Aldrich (US) Main Business
5.3.3 Sigma-Aldrich (US) Gene Knockdown Products, Services and Solutions
5.3.4 Sigma-Aldrich (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.3.5 Abnova (Taiwan) Recent Developments
5.4 Abnova (Taiwan)
5.4.1 Abnova (Taiwan) Profile
5.4.2 Abnova (Taiwan) Main Business
5.4.3 Abnova (Taiwan) Gene Knockdown Products, Services and Solutions
5.4.4 Abnova (Taiwan) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.4.5 Abnova (Taiwan) Recent Developments
5.5 Agilent Technologies (US)
5.5.1 Agilent Technologies (US) Profile
5.5.2 Agilent Technologies (US) Main Business
5.5.3 Agilent Technologies (US) Gene Knockdown Products, Services and Solutions
5.5.4 Agilent Technologies (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.5.5 Agilent Technologies (US) Recent Developments
5.6 Bio-Rad (US)
5.6.1 Bio-Rad (US) Profile
5.6.2 Bio-Rad (US) Main Business
5.6.3 Bio-Rad (US) Gene Knockdown Products, Services and Solutions
5.6.4 Bio-Rad (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.6.5 Bio-Rad (US) Recent Developments
5.7 Cell Signaling Technology (US)
5.7.1 Cell Signaling Technology (US) Profile
5.7.2 Cell Signaling Technology (US) Main Business
5.7.3 Cell Signaling Technology (US) Gene Knockdown Products, Services and Solutions
5.7.4 Cell Signaling Technology (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.7.5 Cell Signaling Technology (US) Recent Developments
5.8 GeneCopoeia (US)
5.8.1 GeneCopoeia (US) Profile
5.8.2 GeneCopoeia (US) Main Business
5.8.3 GeneCopoeia (US) Gene Knockdown Products, Services and Solutions
5.8.4 GeneCopoeia (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.8.5 GeneCopoeia (US) Recent Developments
5.9 siTOOLs Biotech (Germany)
5.9.1 siTOOLs Biotech (Germany) Profile
5.9.2 siTOOLs Biotech (Germany) Main Business
5.9.3 siTOOLs Biotech (Germany) Gene Knockdown Products, Services and Solutions
5.9.4 siTOOLs Biotech (Germany) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.9.5 siTOOLs Biotech (Germany) Recent Developments
5.10 Novus Biologicals (US)
5.10.1 Novus Biologicals (US) Profile
5.10.2 Novus Biologicals (US) Main Business
5.10.3 Novus Biologicals (US) Gene Knockdown Products, Services and Solutions
5.10.4 Novus Biologicals (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.10.5 Novus Biologicals (US) Recent Developments
5.11 EMD Millipore (US)
5.11.1 EMD Millipore (US) Profile
5.11.2 EMD Millipore (US) Main Business
5.11.3 EMD Millipore (US) Gene Knockdown Products, Services and Solutions
5.11.4 EMD Millipore (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.11.5 EMD Millipore (US) Recent Developments
5.12 BioVision (US)
5.12.1 BioVision (US) Profile
5.12.2 BioVision (US) Main Business
5.12.3 BioVision (US) Gene Knockdown Products, Services and Solutions
5.12.4 BioVision (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.12.5 BioVision (US) Recent Developments
5.13 Creative Biomart (US)
5.13.1 Creative Biomart (US) Profile
5.13.2 Creative Biomart (US) Main Business
5.13.3 Creative Biomart (US) Gene Knockdown Products, Services and Solutions
5.13.4 Creative Biomart (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.13.5 Creative Biomart (US) Recent Developments
5.14 Selleck Chemicals (US)
5.14.1 Selleck Chemicals (US) Profile
5.14.2 Selleck Chemicals (US) Main Business
5.14.3 Selleck Chemicals (US) Gene Knockdown Products, Services and Solutions
5.14.4 Selleck Chemicals (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.14.5 Selleck Chemicals (US) Recent Developments
5.15 MyBioSource (US)
5.15.1 MyBioSource (US) Profile
5.15.2 MyBioSource (US) Main Business
5.15.3 MyBioSource (US) Gene Knockdown Products, Services and Solutions
5.15.4 MyBioSource (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.15.5 MyBioSource (US) Recent Developments
5.16 Invitrogen (US)
5.16.1 Invitrogen (US) Profile
5.16.2 Invitrogen (US) Main Business
5.16.3 Invitrogen (US) Gene Knockdown Products, Services and Solutions
5.16.4 Invitrogen (US) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.16.5 Invitrogen (US) Recent Developments
5.17 Qiagen (Germany)
5.17.1 Qiagen (Germany) Profile
5.17.2 Qiagen (Germany) Main Business
5.17.3 Qiagen (Germany) Gene Knockdown Products, Services and Solutions
5.17.4 Qiagen (Germany) Gene Knockdown Revenue (US$ Million) & (2018-2023)
5.17.5 Qiagen (Germany) Recent Developments
6 North America
6.1 North America Gene Knockdown Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gene Knockdown Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gene Knockdown Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gene Knockdown Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gene Knockdown Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gene Knockdown Market Dynamics
11.1 Gene Knockdown Industry Trends
11.2 Gene Knockdown Market Drivers
11.3 Gene Knockdown Market Challenges
11.4 Gene Knockdown Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
